Based on our observations, E7 RNA-LPX vaccination rendered poorly immune-infiltrated and cold TC-1 tumors immunologically hot, whereas LRT-mediated tumor cell death, reduced tumor cell count and diminished intratumoral hypoxia, which in turn appeared to result in more potent and durable vaccine-primed E7-specific CD8+T cell responses during later treatment time points. Here, CD8A is linked to neoplasm.